Values as of: 2024-10-30
COMMON STOCK | Medical Devices |
Last Closing
USD 17.5Change
-1.50 (-7.89)%Market Cap
USD 20.67BVolume
0.04MAnalyst Target
N/AVerdict
Verdict
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide solution for pain management in sports medicine and physical therapy. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
Company Website : https://sanuwave.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 63.76B |
| SMMNY | Siemens Healthineers AG ADR |
-0.42 (-1.58%) |
USD 62.17B |
| RYLPF | Koninklijke Philips N.V |
N/A |
USD 29.83B |
| SONVF | Sonova Holding AG |
N/A |
USD 22.04B |
| SNNUF | Smith & Nephew plc |
+0.01 (+0.03%) |
USD 12.78B |
| WILLF | Demant A/S |
N/A |
USD 8.72B |
| GNGBF | Getinge AB |
N/A |
USD 5.12B |
| AMBFF | Ambu A/S |
N/A |
USD 4.94B |
| AMBBY | Ambu A/S |
N/A |
USD 4.94B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 3.10B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 258.97% | 90% | A- | 90% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 258.97% | 90% | A- | 90% | A- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 221.84% | 89% | A- | 89% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 221.84% | 89% | A- | 89% | A- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -66.67% | 40% | F | 29% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -66.67% | 40% | F | 29% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -33.64% | 11% | F | 6% | D- | ||
| Dividend Return | -33.64% | 11% | F | 6% | D- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 80.93% | 44% | F | 38% | F | ||
| Risk Adjusted Return | -41.56% | 23% | F | 17% | F | ||
| Market Capitalization | 20.67B | 96% | N/A | 95% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
